Clinical Trial Detail

NCT ID NCT03286114
Title Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors University of Michigan Cancer Center
Indications

myelodysplastic syndrome

acute lymphoblastic leukemia

acute myeloid leukemia

Therapies

Pembrolizumab

Age Groups: adult senior

No variant requirements are available.